ClinicalTrials.gg
CompletedNCT05480579Updated Oct 11, 2023

A Study of IBI311 in Healthy Volunteers

A Phase 1 interventional study of placebo and IBI311 in Healthy, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-11.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

It is designed for Multi-center, double-masked, randomized, placebo- control study with dose escalation phase I trial to evaluate the safety, tolerability, PK and immunogenicity profiles of a single intravenous injection of IBI311 in healthy volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to sign form and comply with visit and study procedures per protocol.
  2. Male or female subjects with age of 18\~45 yrs.
  3. Female subjects of childbearing age or male subjects with childbearing age female partner agree to take effective measures from the screening period to 120 days after the end of treatment.

Exclusion criteria

Exclusion Criteria:

  1. Have a history of or any evidence of chronic diseases of liver, kidney, cardiovascular, nervous/mental, digestive tract, respiratory, urinary and endocrine systems.
  2. Have received prior treatment with another anti-IGF-1R monoclonal antibody.
  3. History of drug, alcohol, or chemical abuse within 6 months prior to screening.
  4. History of positive antibody, antibody, Syphilis check, positive during screening period.
  5. Receipt of a within 180 days prior to screening or expected to receive live vaccine during study period.
  6. History of recurrent significant infection or history of recurrent bacterial infections.
  7. Must not have a history of tinnitus or hearing impairment.
  8. Must not have received an agent for any condition within 90 days.
  9. Female volunteers must not be pregnant or lactating.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Cohort 1: treated with different doses of single intravenous injection of IBI311

    Biological: IBI311

  • Placebo comparator
    Cohort 1: placebo group

    Biological: placebo

Interventions

  • Biologicalplacebo

    Dose4 placebo of single IV injection

  • BiologicalIBI311

    Dose2 IBI311 of single IV injection

  • BiologicalIBI311

    Dose4 IBI311 of single IV injection

  • Biologicalplacebo

    Dose3 placebo of single IV injection

  • Biologicalplacebo

    Dose1 placebo of single IV injection

  • BiologicalIBI311

    Dose1 IBI311 of single IV injection

  • BiologicalIBI311

    Dose 3 IBI311 of single IV injection

  • Biologicalplacebo

    Dose2 placebo of single IV injection

06

What researchers measure

Primary outcomes

  1. Incidence, relatedness and severity of all adverse events, treatment emergent adverse events and serious adverse events

    Time frame: Up to 16 weeks

Secondary outcomes

  1. maximum concentration (Cmax)

    PK parameters maximum concentration (Cmax) of IBI311

    Time frame: Up to 16 weeks.

  2. area under the curve (AUC)

    PK parameters area under the curve (AUC) of IBI311

    Time frame: Up to 16 weeks.

  3. half-life (t1/2)

    PK parameters half-life (t1/2) of IBI311

    Time frame: Up to 16 weeks.

  4. the incidence of ADA

    Positive rate of anti-drug antibody

    Time frame: Up to 16 weeks

07

Study locations

1 site
  • Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
    Shanghai, Shanghai 200041, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Nov 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2022
First posted
Jul 29, 2022
StartActual
Aug 10, 2022
Primary completionActual
Nov 23, 2022
CompletionActual
Jan 19, 2023
Last update
Oct 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05480579
Responsible party
Sponsor
First posted
Jul 29, 2022
Start date
Aug 10, 2022
Primary completion
Nov 23, 2022
Completion
Jan 19, 2023
Last update
Oct 11, 2023

Study contacts

Yongfang Yuan, Ph D.
principal investigator · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI311

Start the discussion